UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Delaware 47-5195942 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...

Ulixacaltamide (PRAX-944) for Essential Tremor (ET) and Parkinson's Disease - Praxis plans to initiate Phase 3 trial for Essential Tremor in the second half of 2023[24] - Approximately 1 million people in the United States are diagnosed with ET and on treatment, while another estimated 1 million patients remain untreated[32] - About 40% of patients who seek treatment for ET discontinue within 2 years, which translates to roughly 200,000 patients annually[34] - In the Essential1 Phase 2b ET study, ulixacaltamide showed an improvement of -301 in mADL compared to -144 with placebo (p=0126), and an improvement of -36 in ADL compared to -107 with placebo (p = 0026) [48] - In the mITT analysis excluding ET patients with intention tremor, ulixacaltamide showed an improvement of -312 in mADL compared to -041 with placebo (p=0032), and an improvement of -286 in mADL excluding PS compared to -001 with placebo (p = 0008)[61] PRAX-562 for SCN2A, SCN8A & Other DEEs - Praxis anticipates topline results from the Phase 2 EMBOLD study in the fourth quarter of 2023[69] - PRAX-562 demonstrated a therapeutic index of 172x in preclinical studies[83] - PRAX-562 has been generally well tolerated in over 130 healthy volunteers in Phase 1 trials[90] PRAX-628 for Focal Epilepsy - Praxis plans to initiate a study for Focal Epilepsy in the fourth quarter of 2023[98] - Focal epilepsy affects approximately 2 million people in the US, representing 60% of epilepsy cases[99, 100] PRAX-222 for SCN2A-GoF ASO - Praxis expects topline safety results from the first dose cohort (Part 1) of the EMBRAVE Study in the second half of 2023[118]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...

Financial Performance - The company reported net losses of $214.0 million and $167.1 million for the years ended December 31, 2022 and 2021, respectively[437]. - As of December 31, 2022, the company had an accumulated deficit of $530.6 million[438]. - The net loss for the year ended December 31, 2022, was $214.029 million, compared to a net loss of $167.061 million in 2021, reflecting an increase of $46.968 million (28.1%) year-over-year[461]. - Comprehensive loss for 2022 was $214,026,000, compared to a comprehensive loss of $167,237,000 in 2021, indicating an increase of about 28.0%[517]. - The company expects to continue generating operating losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern[534]. Cash Flow and Liquidity - Cash, cash equivalents, and marketable securities as of December 31, 2022, were $100.5 million, which is expected to fund operations into the first quarter of 2024[441]. - Net cash used in operating activities for 2022 was $185.043 million, compared to $124.554 million in 2021, indicating a significant increase in cash outflow[468]. - Cash and cash equivalents decreased from $138,704,000 in 2021 to $61,615,000 in 2022, a decline of about 55.6%[511]. - The company anticipates continued operating losses and negative cash flows for the foreseeable future, with a need for additional capital to finance operations[477]. Research and Development - Research and development expenses for 2022 totaled $155.0 million, an increase from $120.3 million in 2021[450]. - The company expects substantial increases in expenses related to ongoing research and development activities, particularly for clinical trials and product candidates[475]. - The company plans to advance its lead product candidate, ulixacaltamide, to late-stage clinical trials for essential tremor and Parkinson's disease in 2023[435]. - Accrued research and development expenses totaled $10.7 million as of December 31, 2022, including costs related to the ulixacaltamide Essential1 clinical trial[506]. Operating Expenses - Total operating expenses for the year ended December 31, 2022, were $214.986 million, an increase of $47.654 million (28.5%) compared to $167.332 million in 2021[461]. - General and administrative expenses are anticipated to increase as the company expands its headcount to support growth in research and development activities[456]. - The increase in general and administrative expenses was $12.871 million (27.4%), primarily due to an increase in personnel-related costs[463]. Stock and Financing - The company raised $526.0 million in aggregate cash proceeds from various stock offerings since inception, net of issuance costs[466]. - The company issued and sold 3,595,273 shares under the Sales Agreement in 2022, generating net proceeds of $9.6 million[467]. - The total shares of authorized common stock reserved for future issuance increased from 10,230,564 in 2021 to 12,072,855 in 2022[622]. Assets and Liabilities - Total current assets decreased from $287,409,000 in 2021 to $110,840,000 in 2022, a decline of approximately 61.5%[511]. - Total assets decreased from $292,747,000 in 2021 to $115,128,000 in 2022, representing a reduction of about 60.7%[511]. - Total stockholders' equity decreased from $250,812,000 in 2021 to $76,106,000 in 2022, a decrease of approximately 69.6%[511]. Collaboration and Agreements - A collaboration agreement is expected to result in the recognition of $5.0 million of revenue upon satisfaction of performance obligations[446]. - The Company entered into a Collaboration Agreement with UCB, receiving a $5.0 million upfront payment and potential future payments totaling up to $98.5 million[613]. - Under the license agreement with RogCon, the company may owe a milestone payment of $3.0 million and profit share payments based on a low-double-digit percentage of net profits[484]. Risks and Uncertainties - The company has suffered recurring losses and has limited financial resources, raising substantial doubt about its ability to continue as a going concern[501]. - The company relies on a small number of third-party manufacturers for the supply of materials for its research and development activities, which poses a risk to its operations[549]. - The company is exposed to interest rate fluctuations, but a 100 basis point change would not materially impact its financial position due to the short-term nature of its investments[492].

PRAXIS 0 CORPORATE OVERVIEW November 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical resul ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or o ...

Pipeline Overview - Praxis is developing new classes of treatments inspired by the genetics of epilepsy, targeting common and rare diseases connected by neuronal imbalance[3, 6, 11] - Praxis has a broad CNS portfolio with uncorrelated program risk and a deep early-stage pipeline enabling continuous advancement of new programs[16] - Praxis anticipates a milestone-rich second half of 2022, including Phase 2a Part B topline results for PRAX-944 in Essential Tremor (ET), initiating a Phase 2 trial for PRAX-944 in Parkinson's Disease (PD), and initiating a Phase 2 study for PRAX-222 in SCN2A-DEE[17, 22, 27] PRAX-944 for Movement Disorders - The US ET market represents a $4B+ opportunity[37] - Approximately 50% of patients discontinue medication due to limited efficacy and poor tolerability[33] - PRAX-944 is a differentiated, selective T-type calcium channel blocker with potential for effectiveness across a range of neuronal activity levels[42] - In a Phase 2a study, patients treated with PRAX-944 showed a 42% mean improvement in modified ADLs from baseline, while withdrawal of PRAX-944 resulted in regression to baseline severity with a 139% worsening[48] Epilepsy Portfolio - Praxis is delivering first and best-in-class precision medicines for 25,000+ rare epilepsy patients[75] - The US diagnosed prevalence for rare epilepsy programs represents a $742 million market in 2021 sales, estimated to grow to $1.5 billion in 2026[76] - Preclinical and emerging clinical data demonstrate PRAX-562 will be a first- and best-in-class NaV blocker for DEEs[78] - In Part A of Phase 1 study, dosing with 90 mg of PRAX-562 over 28 days resulted in concentrations that exceeded the EC50 in the MES model by 13-fold[94]

PART I. FINANCIAL INFORMATION This section presents the company's unaudited financial statements and management's analysis of its financial condition and operational results [Item 1. Financial Statements (Unaudited)](index=7&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for Praxis Precision Medicines, Inc., including balance sheets, statements of operations, comprehensive loss, stockholders' equity, and cash flows, along with accompanying notes. The company reported a significant net loss and accumulated deficit, highlighting its early-stage nature and ongoing need for capital [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20as%20of%20June%2030%2C%202022%20and%20December%2031%2C%202021) This section provides a snapshot of the company's financial position at specific dates, detailing assets, liabilities, and stockholders' equity Condensed Consolidated Balance Sheet Highlights (Amounts in thousands) | Metric | June 30, 2022 | December 31, 2021 | | :-------------------------------- | :------------ | :------------------ | | Total current assets | $175,580 | $287,409 | | Total assets | $180,417 | $292,747 | | Total current liabilities | $38,538 | $38,434 | | Total liabilities | $41,548 | $41,935 | | Total stockholders' equity | $138,869 | $250,812 | [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202022%20and%202021) This section details the company's revenues, expenses, and net loss over specific periods, reflecting operational performance Condensed Consolidated Statements of Operations Highlights (Amounts in thousands, except per share data) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $43,620 | $25,678 | $96,272 | $43,607 | | General and administrative | $16,774 | $10,805 | $32,971 | $20,295 | | Total operating expenses | $60,394 | $36,483 | $129,243 | $63,902 | | Net loss | $(60,194) | $(36,401) | $(128,911) | $(63,774) | | Net loss per share, basic and diluted | $(1.32) | $(0.88) | $(2.83) | $(1.59) | [Condensed Consolidated Statements of Comprehensive Loss](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202022%20and%202021) This section presents the company's net loss and other comprehensive income/loss components, showing total comprehensive loss Condensed Consolidated Statements of Comprehensive Loss Highlights (Amounts in thousands) | Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net loss | $(60,194) | $(36,401) | $(128,911) | $(63,774) | | Net unrealized (losses) gains on marketable securities, net of tax | $(74) | $36 | $(504) | $(50) | | Comprehensive loss | $(60,268) | $(36,365) | $(129,415) | $(63,824) | [Condensed Consolidated Statements of Stockholders' Equity](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202022%20and%202021) This section outlines changes in the company's equity accounts, including common stock, additional paid-in capital, and accumulated deficit Changes in Stockholders' Equity (Six Months Ended June 30, 2022) (Amounts in thousands, except share data) | Item | Shares | Amount (Common Stock) | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders' Equity | | :------------------------------------------ | :------- | :-------------------- | :------------------------- | :------------------ | :----------------------------------- | :------------------------- | | Balance at December 31, 2021 | 45,300,514 | $5 | $567,598 | $(316,615) | $(176) | $250,812 | | Stock-based compensation expense | — | — | $15,497 | — | — | $15,497 | | Issuance of common stock from at-the-market public offerings, net of issuance costs | 70,410 | — | $1,368 | — | — | $1,368 | | Net loss | — | — | — | $(128,911) | — | $(128,911) | | Balance at June 30, 2022 | 45,575,406 | $5 | $585,070 | $(445,526) | $(680) | $138,869 | [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202022%20and%202021) This section details the cash inflows and outflows from operating, investing, and financing activities over specific periods Condensed Consolidated Statements of Cash Flows Highlights (Six Months Ended June 30) (Amounts in thousands) | Cash Flow Activity | 2022 | 2021 | | :----------------- | :---------- | :---------- | | Operating activities | $(111,318) | $(55,735) | | Investing activities | $26,340 | $(164,239) | | Financing activities | $1,713 | $99,661 | | Net decrease in cash, cash equivalents and restricted cash | $(83,265) | $(120,313) | | Cash, cash equivalents and restricted cash, end of period | $56,455 | $176,895 | [Notes to Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and additional information supporting the condensed consolidated financial statements [1. Nature of the Business](index=13&type=section&id=1.%20Nature%20of%20the%20Business) This section provides details on 1. nature of the business - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, specifically those characterized by neuronal excitation-inhibition imbalance. The company leverages genetic insights and a precision approach to target rare and prevalent neurological disorders[37](index=37&type=chunk) - The company has incurred significant losses since its inception, with a **net loss of $128.9 million** for the six months ended June 30, 2022, and an **accumulated deficit of $445.5 million**. It anticipates continued operating losses and will require additional capital to fund future operations[41](index=41&type=chunk)[42](index=42&type=chunk) - As of June 30, 2022, the company's **cash, cash equivalents, and marketable securities totaled $165.4 million**, expected to fund operations for at least one year from the financial statement issuance date[42](index=42&type=chunk) [2. Summary of Significant Accounting Policies](index=14&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) This section provides details on 2. summary of significant accounting policies - The condensed consolidated financial statements are prepared in conformity with GAAP and reflect normal recurring adjustments. Management uses estimates and assumptions, such as for accrued **R&D** expenses and stock-based compensation, which may differ from actual results[44](index=44&type=chunk)[46](index=46&type=chunk)[48](index=48&type=chunk) - No recently issued accounting pronouncements are expected to have a material impact on the financial statements[49](index=49&type=chunk) [3. Marketable Securities](index=15&type=section&id=3.%20Marketable%20Securities) This section provides details on 3. marketable securities Marketable Securities Portfolio (Amounts in thousands) | Security Type | Cost (June 30, 2022) | Estimated Fair Value (June 30, 2022) | Cost (December 31, 2021) | Estimated Fair Value (December 31, 2021) | | :-------------------------------- | :------------------- | :--------------------------- | :----------------------- | :--------------------------- | | Corporate debt securities | $45,039 | $44,430 | $83,881 | $83,712 | | Commercial paper | $32,958 | $32,958 | $34,993 | $34,993 | | Debt securities issued by U.S. government agencies | $32,048 | $31,977 | $12,111 | $12,103 | | Other debt securities | — | — | $6,398 | $6,399 | | Total available-for-sale securities | $110,045 | $109,365 | $137,383 | $137,207 | - As of June 30, 2022, the company held **13 securities** with a total fair market value of **$76.4 million** in an unrealized loss position, primarily due to changes in market interest rates. Management believes these losses are temporary and expects full recovery at maturity[51](index=51&type=chunk) [4. Fair Value Measurements](index=15&type=section&id=4.%20Fair%20Value%20Measurements) This section provides details on 4. fair value measurements Financial Assets Measured at Fair Value (Amounts in thousands) | Asset Type | Level 1 (June 30, 2022) | Level 2 (June 30, 2022) | Total (June 30, 2022) | | :-------------------------------- | :---------------------- | :---------------------- | :-------------------- | | Money market funds | $35,552 | — | $35,552 | | Corporate debt securities | — | $44,430 | $44,430 | | Commercial paper | — | $32,958 | $32,958 | | Debt securities issued by U.S. government agencies | $31,977 | — | $31,977 | | **Total** | **$67,529** | **$77,388** | **$144,917** | - The company categorizes financial assets measured at fair value using a hierarchy: Level 1 for unadjusted quoted prices in active markets and Level 2 for quoted prices for similar assets or inputs observable indirectly[53](index=53&type=chunk)[54](index=54&type=chunk) [5. Accrued Expenses](index=16&type=section&id=5.%20Accrued%20Expenses) This section details the company's accrued liabilities, including research and development and personnel-related expenses Accrued Expenses (Amounts in thousands) | Accrued Expense Type | June 30, 2022 | December 31, 2021 | | :-------------------------------- | :------------ | :------------------ | | Accrued external research and development expenses | $20,067 | $17,763 | | Accrued personnel-related expenses | $2,420 | $7,180 | | Accrued other | $3,281 | $1,901 | | **Total accrued expenses** | **$25,768** | **$26,844** | [6. Commitments and Contingencies](index=16&type=section&id=6.%20Commitments%20and%20Contingencies) This section provides details on 6. commitments and contingencies - The company has a sublease agreement for office space in Boston, MA, expiring January 31, 2026, with annual rent increases of approximately **2%**. A letter of credit secures the security deposit, reflected as restricted cash[56](index=56&type=chunk) [7. Common Stock and Preferred Stock](index=17&type=section&id=7.%20Common%20Stock%20and%20Preferred%20Stock) This section provides details on 7. common stock and preferred stock Shares Reserved for Future Issuance | Category | June 30, 2022 | December 31, 2021 | | :------------------------------------------ | :------------ | :------------------ | | Shares reserved for exercise of outstanding stock options | 9,826,672 | 6,468,501 | | Shares reserved for future awards under the 2020 Stock Option and Incentive Plan | 957,739 | 2,667,780 | | Shares reserved for future awards under the 2020 Employee Stock Purchase Plan | 929,661 | 654,204 | | Shares reserved for vesting of restricted stock units | 856,287 | 440,079 | | **Total shares of authorized common stock reserved for future issuance** | **12,570,359**| **10,230,564** | - As of June 30, 2022, the company had **150,000,000** authorized common shares (**$0.0001** par value) with **45,575,406 shares** issued and outstanding. No preferred stock was issued or outstanding[18](index=18&type=chunk)[57](index=57&type=chunk)[59](index=59&type=chunk) [8. Stock-Based Compensation](index=17&type=section&id=8.%20Stock-Based%20Compensation) This section provides details on 8. stock-based compensation Stock-Based Compensation Expense (Amounts in thousands) | Category | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $2,987 | $2,031 | $6,201 | $4,349 | | General and administrative | $4,624 | $3,369 | $9,296 | $5,717 | | **Total stock-based compensation expense** | **$7,611** | **$5,400** | **$15,497** | **$10,066** | - As of June 30, 2022, total unrecognized compensation cost for unvested restricted stock units was **$18.6 million** (weighted-average period of **3.11 years**) and for unvested stock options was **$65.3 million** (weighted-average period of **2.59 years**)[64](index=64&type=chunk)[66](index=66&type=chunk) [9. Net Loss per Share](index=19&type=section&id=9.%20Net%20Loss%20per%20Share) This section provides details on 9. net loss per share Potential Common Shares Excluded from Diluted Net Loss per Share Calculation | Category | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2022 | | :------------------------------------------ | :------------------------------- | :----------------------------- | | Outstanding stock options | 9,826,672 | 9,826,672 | | Unvested restricted stock units | 856,287 | 856,287 | | Potential shares issuable under the 2020 ESPP | 55,244 | 55,244 | | **Total excluded shares** | **10,738,203** | **10,738,203** | [10. Related Party Transactions](index=19&type=section&id=10.%20Related%20Party%20Transactions) This section provides details on 10. related party transactions - Praxis has a Cooperation and License Agreement with RogCon Inc. for SCN2A gene-related epilepsy and neurodevelopmental disorders. As of June 30, 2022, **$0.3 million** in accrued expenses were due to RogCon under this agreement[69](index=69&type=chunk) [11. Restructuring](index=19&type=section&id=11.%20Restructuring) This section provides details on 11. restructuring - In June 2022, the company initiated a **strategic realignment** to focus on Movement Disorders and Epilepsy franchises, resulting in a **workforce reduction**. **Total costs of $1.0 million** were incurred, with **$0.6 million** in **R&D** and **$0.4 million** in **G&A** expenses, primarily for severance and benefits[70](index=70&type=chunk)[71](index=71&type=chunk) - As of June 30, 2022, **$0.5 million** of these costs were paid, with the remaining **$0.5 million** included in accrued expenses and expected to be disbursed by December 31, 2022[72](index=72&type=chunk) [12. Subsequent Events](index=19&type=section&id=12.%20Subsequent%20Events) This section provides details on 12. subsequent events - The company concluded that no subsequent events requiring disclosure occurred between the balance sheet date and the issuance of the condensed consolidated financial statements[73](index=73&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial condition and operational results, highlighting its clinical-stage status, significant losses, and strategic realignment. It details the financial performance for the three and six months ended June 30, 2022, and discusses liquidity, capital resources, and future funding requirements [Overview](index=20&type=section&id=Overview) This section provides details on overview - Praxis is a clinical-stage biopharmaceutical company focused on CNS disorders, with a broad portfolio including three clinical-stage product candidates across movement disorders, epilepsy, and psychiatric disorders[75](index=75&type=chunk) - Key pipeline updates include expected topline results from the Phase 2b trial for PRAX-944 in essential tremor (**Q4 2022**), initiation of Phase 2 studies for PRAX-562 in rare pediatric DEEs (**H2 2022**), and initiation of a first-in-patient study for PRAX-222 (**H2 2022**) after an FDA clinical hold resolution[76](index=76&type=chunk)[77](index=77&type=chunk) - The Phase 2/3 Aria Study for PRAX-114 in major depressive disorder did not meet its primary endpoint, leading to the discontinuation of further enrollment in related psychiatric studies[79](index=79&type=chunk) - The company has incurred a **net loss of $128.9 million** for the six months ended June 30, 2022, and an **accumulated deficit of $445.5 million**, expecting significant operating losses for the foreseeable future[81](index=81&type=chunk) [Restructuring](index=22&type=section&id=Restructuring) This section provides details on restructuring - In June 2022, Praxis underwent a **strategic realignment** to concentrate resources on its Movement Disorders and Epilepsy franchises, resulting in a **workforce reduction**[86](index=86&type=chunk) - The **realignment incurred $1.0 million** in costs, with **$0.6 million** recognized in **R&D** and **$0.4 million** in **G&A** expenses, primarily for employee severance and benefits. **$0.5 million** of these costs were paid by June 30, 2022, with the remainder expected by December 31, 2022[87](index=87&type=chunk)[88](index=88&type=chunk) [COVID-19 Business Update](index=22&type=section&id=COVID-19%20Business%20Update) This section provides details on covid-19 business update - The COVID-19 pandemic has caused some disruptions and increased risks, including slower patient enrollment in clinical trials, but has not significantly impacted overall clinical trial timelines or had material financial impacts to date[89](index=89&type=chunk) - The company continues to monitor the pandemic and evolve its business continuity plans, acknowledging potential future adverse effects on its business, financial condition, and results of operations due to global economic slowdown and healthcare system disruptions[89](index=89&type=chunk) [Financial Operations Overview](index=22&type=section&id=Financial%20Operations%20Overview) This section provides an overview of the company's revenue, operating expenses, other income, and income tax policies [Revenue](index=22&type=section&id=Revenue) This section provides details on revenue - Praxis has not generated any revenue from product sales since its inception and does not anticipate doing so for several years, if at all, as all product candidates are in preclinical or clinical development[90](index=90&type=chunk) [Operating Expenses](index=22&type=section&id=Operating%20Expenses) This section details the company's research and development and general and administrative expenses [Research and Development Expense](index=23&type=section&id=Research%20and%20Development%20Expense) This section provides details on research and development expense Research and Development Expenses by Franchise (Amounts in thousands) | Franchise/Category | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 | | :------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Psychiatry | $11,314 | $6,640 | $25,752 | $9,841 | | Epilepsy | $10,685 | $5,839 | $24,949 | $10,765 | | Movement disorders | $8,411 | $3,795 | $17,515 | $5,372 | | Other exploratory CNS indications | $248 | $819 | $2,439 | $1,482 | | Personnel-related (including stock-based compensation) | $10,735 | $6,745 | $21,876 | $13,250 | | Other indirect research and development expenses | $2,227 | $1,840 | $3,741 | $2,897 | | **Total research and development expenses** | **$43,620** | **$25,678** | **$96,272** | **$43,607** | - **R&D** expenses are expensed as incurred, with external development costs recognized based on task completion. A significant portion of **R&D** costs are external, reflecting the company's 'virtual' **R&D** model[92](index=92&type=chunk)[93](index=93&type=chunk) - The company expects **R&D** expenses to be maintained or increase as product candidates advance through development, new candidates are discovered, manufacturing capabilities are built, and therapeutic areas expand[95](index=95&type=chunk) [General and Administrative Expense](index=24&type=section&id=General%20and%20Administrative%20Expense) This section provides details on general and administrative expense - General and administrative expenses primarily include personnel-related costs (salaries, benefits, stock-based compensation) for executive, finance, legal, commercial, and administrative functions, as well as professional fees, insurance, and facility-related expenses[98](index=98&type=chunk) - These expenses are anticipated to increase with headcount growth to support **R&D** and potential commercialization, along with additional IP-related expenses[100](index=100&type=chunk) [Other Income](index=26&type=section&id=Other%20Income) This section provides details on other income - Other income, net, consists of interest income from **cash, cash equivalents, and marketable securities**, and amortization of investment premiums and discounts[101](index=101&type=chunk) [Income Taxes](index=26&type=section&id=Income%20Taxes) This section provides details on income taxes - The company has not recorded U.S. federal or state income tax benefits due to recurring **net losses** since inception and uncertainty of realizing future benefits. The income tax provision for the reported periods was not material[102](index=102&type=chunk) [Results of Operations](index=26&type=section&id=Results%20of%20Operations) This section compares the company's financial performance for the three and six months ended June 30, 2022 and 2021 [Comparison of the Three Months Ended June 30, 2022 and 2021](index=26&type=section&id=Comparison%20of%20the%20Three%20Months%20Ended%20June%2030%2C%202022%20and%202021) This section provides details on comparison of the three months ended june 30, 2022 and 2021 Consolidated Statements of Operations Highlights (Three Months Ended June 30) (Amounts in thousands) | Metric | 2022 | 2021 | Change | | :------------------------ | :---------- | :---------- | :---------- | | Research and development | $43,620 | $25,678 | $17,942 | | General and administrative| $16,774 | $10,805 | $5,969 | | Total operating expenses | $60,394 | $36,483 | $23,911 | | Net loss | $(60,194) | $(36,401) | $(23,793) | [Comparison of the Six Months Ended June 30, 2022 and 2021](index=27&type=section&id=Comparison%20of%20the%20Six%20Months%20Ended%20June%2030%2C%202022%20and%202021) This section provides details on comparison of the six months ended june 30, 2022 and 2021 Consolidated Statements of Operations Highlights (Six Months Ended June 30) (Amounts in thousands) | Metric | 2022 | 2021 | Change | | :------------------------ | :---------- | :---------- | :---------- | | Research and development | $96,272 | $43,607 | $52,665 | | General and administrative| $32,971 | $20,295 | $12,676 | | Total operating expenses | $129,243 | $63,902 | $65,341 | | Net loss | $(128,911) | $(63,774) | $(65,137) | - The **$52.7 million** increase in **R&D** expenses was driven by increased clinical-related spend across psychiatry (**$15.9M**), epilepsy (**$14.2M**, including a **$2.0M** license fee to Ionis Pharmaceuticals), and movement disorders (**$12.1M**), alongside an **$8.6 million** increase in personnel-related costs[108](index=108&type=chunk) - The **$12.7 million** increase in **G&A** expenses was primarily due to an **$8.4 million** increase in personnel-related costs and a **$3.6 million** increase in professional fees, including legal and patent-related work[109](index=109&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=Liquidity%20and%20Capital%20Resources) This section provides details on liquidity and capital resources [Sources of Liquidity](index=28&type=section&id=Sources%20of%20Liquidity) This section provides details on sources of liquidity - Since inception, Praxis has funded operations primarily through equity issuances, raising **$517.8 million** in **aggregate cash proceeds** (net of issuance costs) through June 30, 2022[111](index=111&type=chunk) - As of June 30, 2022, the company held **$165.4 million** in **cash, cash equivalents, and marketable securities**[111](index=111&type=chunk) - Under an Open Market Sale Agreement with Jefferies LLC, the company sold **70,410 shares** for **$1.4 million net proceeds** during the six months ended June 30, 2022, with a total of **$8.4 million** raised from **462,407 shares** since the agreement's inception[112](index=112&type=chunk)[113](index=113&type=chunk) [Historical Cash Flows](index=29&type=section&id=Historical%20Cash%20Flows) This section provides details on historical cash flows Summary of Cash Flows (Six Months Ended June 30) (Amounts in thousands) | Cash Flow Activity | 2022 | 2021 | | :----------------- | :---------- | :---------- | | Operating activities | $(111,318) | $(55,735) | | Investing activities | $26,340 | $(164,239) | | Financing activities | $1,713 | $99,661 | | Net decrease in cash, cash equivalents and restricted cash | $(83,265) | $(120,313) | [Plan of Operation and Future Funding Requirements](index=29&type=section&id=Plan%20of%20Operation%20and%20Future%20Funding%20Requirements) This section provides details on plan of operation and future funding requirements - The company expects substantial increases in expenses due to ongoing **R&D** activities and clinical trials, leading to continued operating losses and negative operating cash flows[121](index=121&type=chunk) - The **strategic realignment** in June 2022, focusing on Movement Disorders and Epilepsy, is expected to reduce future operating expenses and extend the cash runway[122](index=122&type=chunk) - **Current cash, cash equivalents, and marketable securities of $165.4 million** are projected to fund operating expenses and capital expenditures into the **first quarter of 2024**[123](index=123&type=chunk) - Future funding requirements are highly dependent on the scope, progress, and costs of preclinical and clinical development, regulatory approvals, commercialization activities, and intellectual property protection[124](index=124&type=chunk)[126](index=126&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=31&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) This section provides details on critical accounting policies and significant judgments and estimates - There have been no changes to the critical accounting policies from those described in the company's Annual Report on Form 10-K filed on February 28, 2022[131](index=131&type=chunk) [Recently Issued Accounting Pronouncements](index=31&type=section&id=Recently%20Issued%20Accounting%20Pronouncements) This section provides details on recently issued accounting pronouncements - The company does not expect any recently issued accounting pronouncements to have a material impact on its condensed consolidated financial statements[132](index=132&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section addresses the company's exposure to market risks, primarily interest rate sensitivity, given its holdings in cash, cash equivalents, and marketable securities - The company's primary market risk exposure is interest rate sensitivity, affecting its **cash, cash equivalents, and marketable securities**, which are invested in money market funds or U.S. Treasury and government agency obligations[134](index=134&type=chunk) - Due to the short-term nature and low-risk profile of its investment portfolio, a **100 basis point** change in market interest rates is not expected to have a material impact on the fair market value of the portfolio or financial results[134](index=134&type=chunk) [Item 4. Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) This section outlines management's evaluation of the company's disclosure controls and procedures and reports on any changes in internal control over financial reporting [Management's Evaluation of Our Disclosure Controls and Procedures](index=32&type=section&id=Management%27s%20Evaluation%20of%20Our%20Disclosure%20Controls%20and%20Procedures) This section provides details on management's evaluation of our disclosure controls and procedures - As of June 30, 2022, management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level[136](index=136&type=chunk) [Changes in Internal Control Over Financial Reporting](index=32&type=section&id=Changes%20in%20Internal%20Control%20Over%20Financial%20Reporting) This section provides details on changes in internal control over financial reporting - There were no changes in internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[137](index=137&type=chunk) PART II. OTHER INFORMATION This section covers legal proceedings, risk factors, equity sales, and other miscellaneous disclosures [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) This section states that the company is not currently involved in any material legal matters or claims, but acknowledges the potential for future claims arising in the ordinary course of business - As of the report date, Praxis Precision Medicines, Inc. is not a party to any material legal matters or claims[140](index=140&type=chunk) - The company recognizes that it may become involved in legal matters and claims in the ordinary course of business, which could adversely impact its operations due to defense and settlement costs, and diversion of management resources[140](index=140&type=chunk) [Item 1A. Risk Factors](index=33&type=page&id=Item%201A.%20Risk%20Factors) This comprehensive section details the significant risks and uncertainties that could materially affect Praxis Precision Medicines, Inc.'s business, financial condition, and operating results. It covers risks related to financial position, product development, regulatory approval, commercialization, legal compliance, intellectual property, dependence on third parties, employee matters, data privacy, tax laws, and common stock investment [Risks Related to Our Financial Position and Need for Additional Capital](index=33&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) This section outlines risks associated with the company's financial health and its ongoing need for external funding [Risks Related to Past Financial Condition](index=33&type=section&id=Risks%20Related%20to%20Past%20Financial%20Condition) This section provides details on risks related to past financial condition - Praxis is a clinical-stage biopharmaceutical company with no approved products and has incurred significant losses since inception, including a **net loss of $128.9 million** for the six months ended June 30, 2022, and an **accumulated deficit of $445.5 million**[142](index=142&type=chunk) - The company anticipates continued significant losses as it expands research and development, seeks regulatory approvals, and invests in its pipeline and infrastructure[142](index=142&type=chunk)[143](index=143&type=chunk) [Risks Related to Future Financial Condition](index=34&type=section&id=Risks%20Related%20to%20Future%20Financial%20Condition) This section provides details on risks related to future financial condition - Praxis will require substantial additional funding to continue preclinical and clinical development and potential commercialization of its product candidates, with **current capital** expected to fund operations only into **Q1 2024**[145](index=145&type=chunk)[147](index=147&type=chunk) - Failure to raise additional capital on favorable terms could force delays, reductions, or elimination of product development programs or commercialization efforts, and may lead to dilution for existing stockholders if equity financing is pursued[146](index=146&type=chunk)[150](index=150&type=chunk)[151](index=151&type=chunk) [Risks Related to Research and Development and the Biopharmaceutical Industry](index=37&type=section&id=Risks%20Related%20to%20Research%20and%20Development%20and%20the%20Biopharmaceutical%20Industry) This section details the inherent risks in drug development, from preclinical stages to regulatory approval [Risks Related to Preclinical and Clinical Development](index=37&type=section&id=Risks%20Related%20to%20Preclinical%20and%20Clinical%20Development) This section provides details on risks related to preclinical and clinical development - Drug development is a lengthy, complex, and expensive process with uncertain outcomes; preclinical and early clinical trial results may not predict success in later stages, and product candidates can fail at any point[165](index=165&type=chunk) - Regulatory approval processes are unpredictable, and Praxis has no prior experience submitting an NDA. Product candidates may fail to receive approval due to issues with trial design, efficacy, safety, or manufacturing[160](index=160&type=chunk)[161](index=161&type=chunk)[162](index=162&type=chunk) - Undesirable side effects from product candidates could delay or prevent regulatory approval, limit commercial potential, or lead to significant negative consequences post-approval, including withdrawal from the market[175](index=175&type=chunk)[179](index=179&type=chunk) - Difficulties in patient enrollment for clinical trials, influenced by factors like eligibility criteria, patient proximity, and competing trials, could lead to significant delays, increased costs, or abandonment of trials[181](index=181&type=chunk)[182](index=182&type=chunk)[185](index=185&type=chunk) - Interim, topline, and preliminary data from clinical trials are subject to change upon comprehensive review and audit, and may differ materially from final results, potentially impacting regulatory approval and commercialization[187](index=187&type=chunk)[189](index=189&type=chunk) [Risks Related to Regulatory Approval](index=45&type=section&id=Risks%20Related%20to%20Regulatory%20Approval) This section provides details on risks related to regulatory approval - Obtaining regulatory approval in one jurisdiction does not guarantee approval in others, and foreign regulatory processes can involve different requirements, additional trials, and longer review periods[201](index=201&type=chunk)[202](index=202&type=chunk) - Product candidates may be regulated as controlled substances, subjecting them to significant restrictions on manufacture, use, sale, and distribution by agencies like the DEA, potentially limiting commercial potential[204](index=204&type=chunk)[205](index=205&type=chunk)[207](index=207&type=chunk) - The company is exposed to product liability lawsuits from clinical testing or commercialization, which could divert resources, halt trials, incur substantial liabilities, or limit commercialization, despite maintaining insurance coverage[208](index=208&type=chunk)[209](index=209&type=chunk)[210](index=210&type=chunk) [Risks Related to the Commercialization of our Product Candidates](index=47&type=section&id=Risks%20Related%20to%20the%20Commercialization%20of%20our%20Product%20Candidates) This section addresses challenges in marketing and selling approved products, including regulatory compliance and market acceptance [Risks Related to Post-Marketing Regulatory Requirements](index=48&type=section&id=Risks%20Related%20to%20Post-Marketing%20Regulatory%20Requirements) This section provides details on risks related to post-marketing regulatory requirements - Any approved product candidates will be subject to extensive ongoing post-marketing regulatory requirements, including manufacturing, labeling, advertising, and safety reporting, with potential for restrictions or market withdrawal if non-compliance or unforeseen problems occur[217](index=217&type=chunk)[218](index=218&type=chunk)[221](index=221&type=chunk)[222](index=222&type=chunk) - The FDA and other regulatory agencies strictly enforce prohibitions on off-label promotion. Improper promotion could lead to significant liability, fines, and restrictions on promotional conduct[225](index=225&type=chunk)[226](index=226&type=chunk) [Risks Related to Sales, Marketing and Competition](index=50&type=section&id=Risks%20Related%20to%20Sales%2C%20Marketing%20and%20Competition) This section provides details on risks related to sales, marketing and competition - Commercial success depends on significant market acceptance by physicians, patients, and third-party payors. Lack of acceptance could limit revenue and profitability[227](index=227&type=chunk)[228](index=228&type=chunk) - Failure to obtain or maintain adequate coverage and reimbursement from third-party payors (governmental and private) for approved products could limit market access and revenue generation[229](index=229&type=chunk)[230](index=230&type=chunk)[232](index=232&type=chunk) - Governments outside the U.S. often impose strict price controls and reimbursement limitations, which could adversely affect revenues and profitability in foreign markets[237](index=237&type=chunk) - Praxis lacks an internal sales and marketing organization and commercialization experience. Building these capabilities is expensive and risky, and reliance on third parties may result in lower profitability or ineffective market penetration[239](index=239&type=chunk)[240](index=240&type=chunk) - The biopharmaceutical industry is highly competitive, with many competitors possessing greater resources and experience. Competitors may achieve regulatory approval sooner or develop superior therapies, negatively impacting Praxis's market share and financial condition[211](index=211&type=chunk)[212](index=212&type=chunk)[214](index=214&type=chunk)[215](index=215&type=chunk) [Risks Related to Ongoing Regulatory and Legal Compliance](index=53&type=section&id=Risks%20Related%20to%20Ongoing%20Regulatory%20and%20Legal%20Compliance) This section covers risks associated with adhering to healthcare laws, data protection, and international regulations [Risks Related to Healthcare and Related Laws](index=53&type=section&id=Risks%20Related%20to%20Healthcare%20and%20Related%20Laws) This section provides details on risks related to healthcare and related laws - Upon commercialization, Praxis will be subject to extensive federal, state, and foreign healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Sunshine Act). Non-compliance could lead to significant sanctions, fines, and reputational harm[241](index=241&type=chunk)[242](index=242&type=chunk)[243](index=243&type=chunk)[244](index=244&type=chunk) - The company is subject to evolving U.S. federal and state, and foreign data protection laws (e.g., GDPR, CCPA, CPRA) governing personal information. Failure to comply could result in liability, reputational damage, and increased compliance costs[247](index=247&type=chunk)[248](index=248&type=chunk)[249](index=249&type=chunk)[250](index=250&type=chunk)[251](index=251&type=chunk)[252](index=252&type=chunk)[253](index=253&type=chunk)[254](index=254&type=chunk)[256](index=256&type=chunk) - Ongoing healthcare legislative and regulatory reforms, such as the ACA and subsequent amendments, could adversely affect the business by impacting coverage, reimbursement, and drug pricing[257](index=257&type=chunk)[258](index=258&type=chunk)[259](index=259&type=chunk)[260](index=260&type=chunk)[261](index=261&type=chunk)[262](index=262&type=chunk)[263](index=263&type=chunk) - Inadequate funding or disruptions at regulatory agencies (e.g., FDA, SEC) could hinder their ability to review and approve new products in a timely manner, negatively impacting Praxis's business[264](index=264&type=chunk)[265](index=265&type=chunk)[266](index=266&type=chunk) [Risks Related to International Regulations](index=59&type=section&id=Risks%20Related%20to%20International%20Regulations) This section provides details on risks related to international regulations - EU drug marketing and reimbursement regulations, including governmental price controls and anti-kickback provisions, could significantly impact the pricing and usage of products in European member states[267](index=267&type=chunk)[268](index=268&type=chunk)[269](index=269&type=chunk)[270](index=270&type=chunk) - Uncertainty surrounding Brexit may create instability in international markets, currency fluctuations, and increased complexity in regulatory compliance for medicinal products in the UK and EU, potentially delaying commercialization[271](index=271&type=chunk)[272](index=272&type=chunk)[273](index=273&type=chunk)[274](index=274&type=chunk) - International operations are subject to laws like the U.S. Foreign Corrupt Practices Act (FCPA) and export control regulations. Non-compliance could lead to fines, criminal sanctions, and damage to reputation and business prospects[275](index=275&type=chunk)[276](index=276&type=chunk)[277](index=277&type=chunk)[278](index=278&type=chunk)[279](index=279&type=chunk) - Failure to comply with environmental, health, and safety laws and regulations, particularly concerning hazardous materials, could result in fines, penalties, and substantial costs, potentially harming research and development efforts[280](index=280&type=chunk)[281](index=281&type=chunk)[282](index=282&type=chunk) [Risks Related to Our Intellectual Property](index=61&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) This section discusses risks concerning the protection, enforcement, and licensing of the company's intellectual property [Risks Related to Licensed Intellectual Property](index=61&type=section&id=Risks%20Related%20to%20Licensed%20Intellectual%20Property) This section provides details on risks related to licensed intellectual property - Praxis's success depends on obtaining and maintaining patent, trademark, and trade secret protection for its technologies and product candidates. The patenting process is expensive, time-consuming, and uncertain, with risks of patents being narrowed, invalidated, or unenforceable[283](index=283&type=chunk)[284](index=284&type=chunk)[285](index=285&type=chunk)[286](index=286&type=chunk) - The company may not be the first to file patent applications or invent the technology, leading to priority disputes. Recent patent reform legislation (America Invents Act) increases uncertainties and costs in patent prosecution and enforcement[287](index=287&type=chunk)[288](index=288&type=chunk)[290](index=290&type=chunk)[291](index=291&type=chunk) - Failure to protect trade secrets through non-disclosure agreements and security measures could harm the company's competitive position if proprietary information is disclosed, misappropriated, or independently developed by others[297](index=297&type=chunk)[298](index=298&type=chunk)[299](index=299&type=chunk)[300](index=300&type=chunk) - Third-party claims of intellectual property infringement could prevent or delay product discovery and development, leading to expensive litigation, substantial damages, or the need to obtain costly licenses[301](index=301&type=chunk)[303](index=303&type=chunk)[304](index=304&type=chunk) [Risks Related to Patent Laws and Protection](index=68&type=section&id=Risks%20Related%20to%20Patent%20Laws%20and%20Protection) This section provides details on risks related to patent laws and protection - Maintaining patent protection requires compliance with various procedural and fee payment requirements; non-compliance can lead to abandonment or lapse of patent rights[320](index=320&type=chunk)[321](index=321&type=chunk) - Issued patents covering product candidates could be found invalid or unenforceable if challenged in court or by the USPTO, potentially leading to loss of patent protection and adverse impact on commercialization[322](index=322&type=chunk) - Changes in U.S. patent laws or their interpretation, such as the America Invents Act, could increase uncertainties and costs in patent prosecution and enforcement, potentially diminishing the value of patents[324](index=324&type=chunk)[326](index=326&type=chunk)[327](index=327&type=chunk) - Limited foreign intellectual property rights and weaker protection laws in some countries may hinder the ability to prevent infringement or marketing of competing products globally[328](index=328&type=chunk)[329](index=329&type=chunk)[330](index=330&type=chunk) - Patent terms may be inadequate to protect competitive position due to the long development and regulatory review process, potentially leading to early competition upon patent expiration[331](index=331&type=chunk)[332](index=332&type=chunk) - Failure to obtain patent term extension and data exclusivity for product candidates could materially harm the business by allowing competitors to enter the market sooner[333](index=333&type=chunk) [Risks Related to Our Dependence on Third Parties](index=71&type=section&id=Risks%20Related%20to%20Our%20Dependence%20on%20Third%20Parties) This section highlights risks arising from reliance on external partners for research, manufacturing, and supply chain management [Risks Related to Third Parties Generally](index=71&type=section&id=Risks%20Related%20to%20Third%20Parties%20Generally) This section provides details on risks related to third parties generally - Praxis relies heavily on third parties (CROs, laboratories, clinical investigators) for preclinical and clinical trials. Unsatisfactory performance, termination of engagements, or non-compliance with GCPs could delay or prevent regulatory approval and commercialization[335](index=335&type=chunk)[336](index=336&type=chunk)[337](index=337&type=chunk)[338](index=338&type=chunk) - Switching or adding third parties for studies is costly and time-consuming, potentially causing delays. Reliance on third parties for drug supply storage and distribution also poses risks to clinical development and commercialization[339](index=339&type=chunk)[340](index=340&type=chunk) [Risks Related to Third-Party Manufacturers](index=72&type=section&id=Risks%20Related%20to%20Third-Party%20Manufacturers) This section provides details on risks related to third-party manufacturers - The company relies on third-party manufacturers for product candidates, increasing the risk of insufficient quantities or unacceptable costs, which could delay or impair development and commercialization efforts[341](index=341&type=chunk) - Reliance on third-party manufacturers entails risks such as failure to meet schedules, comply with cGMP, or maintain quality control, potentially leading to regulatory sanctions, supply disruptions, and adverse effects on profit margins[342](index=342&type=chunk)[343](index=343&type=chunk)[344](index=344&type=chunk) - Inability of third-party manufacturers to scale production or optimize processes could increase manufacturing costs and delay commercialization[345](index=345&type=chunk) [Risks Related to Third-Party Suppliers](index=73&type=section&id=Risks%20Related%20to%20Third-Party%20Suppliers) This section provides details on risks related to third-party suppliers - Praxis depends on third-party suppliers for key raw materials, some of which are sole sources. Loss of these suppliers or their inability to provide adequate materials could cause significant delays in clinical trials and commercialization[346](index=346&type=chunk)[347](index=347&type=chunk) [Risks Related to Collaborations](index=74&type=section&id=Risks%20Related%20to%20Collaborations) This section provides details on risks related to collaborations - Dependence on third-party collaborators for **R&D** and commercialization of product candidates carries risks, including limited control over resources, potential intellectual property disputes, and collaborators' failure to perform or pursue development[348](index=348&type=chunk)[349](index=349&type=chunk) - Competition for collaborations is significant, and failure to secure favorable terms or integrate product candidates into existing operations could lead to delays, increased expenditures, or inability to generate revenue[350](index=350&type=chunk)[351](index=351&type=chunk) [Risks Related to Employee Matters, Managing Our Business and Operations](index=76&type=section&id=Risks%20Related%20to%20Employee%20Matters%2C%20Managing%20Our%20Business%20and%20Operations) This section addresses risks related to human capital, operational management, and business continuity [Risks Related to Business Operations](index=76&type=section&id=Risks%20Related%20to%20Business%20Operations) This section provides details on risks related to business operations - Business interruptions from the COVID-19 pandemic or similar outbreaks may adversely affect operations, including clinical trial enrollment, regulatory reviews, and supply chains, despite current mitigation efforts[354](index=354&type=chunk)[355](index=355&type=chunk)[356](index=356&type=chunk)[357](index=357&type=chunk) - International operations expose the company to economic, political, and regulatory risks, including inflation, changing foreign regulations, intellectual property enforcement challenges, and geopolitical instability (e.g., Russia-Ukraine conflict)[358](index=358&type=chunk)[359](index=359&type=chunk) [Risks Related to Employees](index=77&type=section&id=Risks%20Related%20to%20Employees) This section provides details on risks related to employees - The company heavily depends on its executive officers and key personnel. The loss of their services, or inability to attract and retain highly qualified managerial, scientific, and medical personnel in a competitive industry, would materially harm the business[360](index=360&type=chunk)[361](index=361&type=chunk)[362](index=362&type=chunk)[365](index=365&type=chunk) - Employees, contractors, and collaborators may engage in misconduct or improper activities, including non-compliance with regulatory standards or fraudulent conduct, which could lead to significant liability, regulatory sanctions, and reputational damage[366](index=366&type=chunk)[367](index=367&type=chunk) - Expected organizational growth, particularly in regulatory affairs and sales/marketing, may lead to difficulties in management, operational mistakes, loss of business opportunities, and increased expenses if not effectively managed[368](index=368&type=chunk)[369](index=369&type=chunk) [Risks Related to Data Privacy](index=80&type=section&id=Risks%20Related%20to%20Data%20Privacy) This section provides details on risks related to data privacy - Cyber-attacks or failures in IT systems (internal or third-party) could result in information theft, data corruption, and significant business disruption, potentially leading to violations of privacy laws, litigation, and reputational harm[370](index=370&type=chunk)[371](index=371&type=chunk) - Reliance on cloud-based software services means any disruption, interference, or unfavorable changes in terms of service by cloud providers could negatively affect operations, business, and reputation[372](index=372&type=chunk)[373](index=373&type=chunk)[374](index=374&type=chunk)[375](index=375&type=chunk) [Risks Related to Tax Laws](index=81&type=section&id=Risks%20Related%20to%20Tax%20Laws) This section provides details on risks related to tax laws - Changes in U.S. federal, state, and local tax laws, including potential increases in corporate income tax rates or new minimum taxes, could adversely affect the company's business and financial condition[376](index=376&type=chunk)[377](index=377&type=chunk) - The company's ability to use its U.S. federal and state net operating loss (NOL) carryforwards and tax credits may be limited by future taxable income generation and potential '**ownership changes**' under Sections 382 and 383 of the Code[378](index=378&type=chunk)[379](index=379&type=chunk)[380](index=380&type=chunk)[381](index=381&type=chunk) [Risks Related to Our Common Stock](index=82&type=section&id=Risks%20Related%20to%20Our%20Common%20Stock) This section outlines risks pertinent to investing in the company's common stock, including price volatility and dilution [Risks Related to Investment in Securities](index=82&type=section&id=Risks%20Related%20to%20Investment%20in%20Securities) This section provides details on risks related to investment in securities - The company's stock price has been and is likely to remain highly volatile, influenced by clinical trial results, regulatory decisions, competition, financial performance, and broader market conditions, potentially leading to loss of investment[382](index=382&type=chunk)[383](index=383&type=chunk)[384](index=384&type=chunk) - Lack of research coverage by industry analysts or unfavorable reports could negatively impact stock price and trading volume[385](index=385&type=chunk) - Praxis does not intend to pay dividends, so stockholder returns will be limited to stock appreciation, and future financing arrangements may restrict dividend payments[386](index=386&type=chunk) - Future issuances of additional capital stock for financings, acquisitions, or incentive plans will dilute existing stockholders' **ownership interests** and could reduce the per-share value of common stock[387](index=387&type=chunk) - Executive officers, directors, and principal stockholders collectively own a significant percentage of **voting stock** (approx. **62.2%** as of Dec 31, 2021), allowing them to exert control over stockholder-approved matters, which could adversely affect the stock price[388](index=388&type=chunk)[389](index=389&type=chunk) [Risks Related to Our Controls and Reporting Requirements](index=84&type=section&id=Risks%20Related%20to%20Our%20Controls%20and%20Reporting%20Requirements) This section provides details on risks related to our controls and reporting requirements - Operating as a public company incurs significant legal, accounting, and compliance costs, requiring substantial management time and potentially diverting resources from core business activities[389](index=389&type=chunk)[390](index=390&type=chunk) - As a smaller reporting company, reduced disclosure obligations may make common stock less attractive to some investors, potentially leading to a less active trading market and increased stock price volatility[391](index=391&type=chunk) - Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports, fraud, loss of investor confidence, and restatements, harming the business and stock price[392](index=392&type=chunk)[393](index=393&type=chunk)[394](index=394&type=chunk) - Disclosure controls and procedures, while designed for reasonable assurance, may not prevent or detect all errors or acts of fraud due to inherent limitations like faulty judgments, simple errors, or circumvention[395](index=395&type=chunk) - Management has broad discretion over **cash** and **cash equivalents**, and ineffective use of these funds could result in financial losses, stock price decline, and delays in product development[396](index=396&type=chunk) [Risks Related to Charter and Bylaws](index=85&type=section&id=Risks%20Related%20to%20Charter%20and%20Bylaws) This section provides details on risks related to charter and bylaws - Anti-takeover provisions in the company's charter documents and Delaware law (Section 203) could delay or prevent a change of control or changes in the board of directors, potentially limiting the market price of common stock[397](index=397&type=chunk)[398](index=398&type=chunk)[399](index=399&type=chunk) - Bylaw provisions designating Delaware courts as the exclusive forum for certain actions may limit stockholders' ability to choose a favorable judicial forum, potentially discouraging lawsuits against the company or its management[400](index=400&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=86&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section reports on the company's unregistered equity sales and the use of proceeds from its public offerings - The company did not make any sales of unregistered equity securities during the three months ended June 30, 2022[401](index=401&type=chunk) - The initial public offering (IPO) in October 2020 involved the issuance and sale of **11,500,000 shares** of common stock at **$19.00** per share[402](index=402&type=chunk) [Item 3. Defaults Upon Senior Securities](index=87&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section states that there are no reportable defaults upon senior securities - This item is not applicable, indicating no defaults upon senior securities[404](index=404&type=chunk) [Item 4. Mine Safety Disclosures](index=87&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section indicates that there are no mine safety disclosures required for the company - This item is not applicable, indicating no mine safety disclosures[405](index=405&type=chunk) [Item 5. Other Information](index=87&type=section&id=Item%205.%20Other%20Information) This section states that there is no other information to report - No other information is reported under this item[406](index=406&type=chunk) [Item 6. Exhibits](index=88&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the Quarterly Report on Form 10-Q, including corporate documents, agreements, and certifications - The exhibits include the Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, a Transition Agreement with Bernard Ravina, and various certifications (e.g., Principal Executive Officer, Principal Financial Officer)[408](index=408&type=chunk) - Certain certifications (Exhibit 32.1) are deemed to accompany the report but are not 'filed' for Section 18 purposes and are not incorporated by reference unless specifically stated[408](index=408&type=chunk) [Signatures](index=89&type=section&id=Signatures) This section contains the required signatures of the registrant's authorized officers, confirming the submission of the report - The report is signed on behalf of Praxis Precision Medicines, Inc. by Marcio Souza, Chief Executive Officer and Director, and Timothy Kelly, Chief Financial Officer, on August 8, 2022[413](index=413&type=chunk)

PRAXIS ● CORPORATE OVERVIEW May 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results an ...